<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769470</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000616008</org_study_id>
    <secondary_id>P30CA016042</secondary_id>
    <secondary_id>TRIO-TORI-B-07</secondary_id>
    <secondary_id>SANOFI-AVENTIS-TRIO-TORI-B-07</secondary_id>
    <secondary_id>WIRB-20080822</secondary_id>
    <nct_id>NCT00769470</nct_id>
    <nct_alias>NCT02668939</nct_alias>
  </id_info>
  <brief_title>Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>A Multicenter, Open Label, Randomized Phase II Trial of Presurgical Treatment With Single-Agent Trastuzumab (H) or Lapatinib (Ty) or the Combination of Trastuzumab and Lapatinib (H+Ty), Followed by Six Cycles of Docetaxel (T) and Carboplatin (C) With Trastuzumab (TCH) or Lapatinib (TCTy) or the Combination of Trastuzumab and Lapatinib (TCHTy) in Patients With HER2/Neu-Amplified Operable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Oncology Research International</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Oncology Research International</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Lapatinib may stop the growth of&#xD;
      tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known&#xD;
      whether docetaxel and carboplatin are more effective when given together with trastuzumab&#xD;
      and/or lapatinib in treating women with stage I, stage II, or stage III breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well docetaxel and carboplatin work&#xD;
      when given together with trastuzumab and/or lapatinib in treating women with stage I, stage&#xD;
      II, or stage III breast cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To investigate the clinical efficacy of neoadjuvant docetaxel and carboplatin in&#xD;
           combination with trastuzumab (Herceptin®) and/or lapatinib ditosylate by estimating the&#xD;
           pathologic complete response (pCR) rate in the breast and axilla of women with&#xD;
           HER2/neu-positive resectable stage I-III adenocarcinoma of the breast.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To estimate the molecular effects of lapatinib ditosylate and trastuzumab alone or in&#xD;
           combination on tumor tissues of these patients by assessing changes in gene expression&#xD;
           using serial gene microarray analysis.&#xD;
&#xD;
        -  To assess for gene expression and/or biomarker changes that may be correlated with or&#xD;
           predict pCR and clinical response to lapatinib ditosylate and/or trastuzumab in these&#xD;
           patients.&#xD;
&#xD;
        -  To evaluate the safety and tolerability of these regimens in these patients.&#xD;
&#xD;
        -  To evaluate the clinical efficacy of these regimens by estimating the clinical objective&#xD;
           response rate (complete response and partial response) in these patients.&#xD;
&#xD;
        -  To estimate the rate of congestive heart failure or drop in LVEF (&gt; 10% points from&#xD;
           baseline and below lower limits of normal) in each of the three treatment arms.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to baseline tumor&#xD;
      size (≤ 3 cm vs &gt; 3 cm) and hormone receptor status (estrogen receptor [ER]- and/or&#xD;
      progesterone receptor [PR]-positive vs ER- and PR- negative). Patients are randomized to 1 of&#xD;
      3 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive a trastuzumab IV over 90 minutes on day 1 in course 1. Patients&#xD;
           receive docetaxel IV, carboplatin IV, and trastuzumab IV over 30 minutes on day 1 in&#xD;
           courses 2-7. Courses repeat every 21 days in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive oral lapatinib ditosylate once daily on days 1-21 in course 1.&#xD;
           Patients receive docetaxel IV, carboplatin IV as in arm I and oral lapatinib ditosylate&#xD;
           once daily on days 1-21 in courses 2-7. Courses repeat every 21 days in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm III: Patients receive trastuzumab IV as in arm I on day 1 and oral lapatinib&#xD;
           ditosylate as in arm II on days 1-21 in course 1. Patients receive docetaxel IV,&#xD;
           carboplatin IV, and trastuzumab IV as in arm I on day 1 and oral lapatinib ditosylate as&#xD;
           in arm II on days 1-21 in courses 2-7. Courses repeat every 21 days in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
      Within 4-6 weeks after completion of chemotherapy, all patients under go definitive surgery&#xD;
      and/or radiotherapy at the discretion of the treating physician. Tumor biopsy and blood&#xD;
      samples are collected for biomarker analysis and molecular analysis at baseline, after course&#xD;
      1, and at the time of definitive breast surgery or completion of chemotherapy. Gene&#xD;
      expression changes are analyzed by mRNA microarray analysis and molecular changes in protein&#xD;
      expression profiles by IHC. Samples may also be analyzed by RT-PCR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response (pCR)</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of pCR rates</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive trastuzumab IV over 90 minutes on day in course 1. Patients receive docetaxel IV, carboplatin IV, and trastuzumab IV over 30 minutes on day 1 in course 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral lapatinib ditosylate once daily on days 1-21 in course 1. Patients receive docetaxel IV and carboplatin IV on day 1 and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7.Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive trastuzumab IV over 90 minutes on day 1 and oral lapatinib ditosylate daily on days 1-21. Starting on day 22, patients receive docetaxel IV, carboplatin IV, and trastuzumab IV three times a week and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib ditosylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged 18 to 70 years, inclusive&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the breast&#xD;
&#xD;
          -  Stage I, II or III disease (early stage) with tumor measuring ≥ 1 cm and meeting any&#xD;
             the following criteria:&#xD;
&#xD;
               -  Grade &gt; 1&#xD;
&#xD;
               -  Estrogen receptor- and progesterone receptor-negative&#xD;
&#xD;
               -  Age ≤ 35 years&#xD;
&#xD;
          -  HER2/neu-positivity by fluorescence in situ hybridization (FISH)&#xD;
&#xD;
          -  Estrogen and progesterone receptor status known prior to study entry.&#xD;
&#xD;
          -  ECOG performance status 0-1 Adequate organ function (ejection fraction&gt;- lower limit&#xD;
             of normal) as determined by MUGA or echocardiogram.&#xD;
&#xD;
          -  If female of childbearing potential, pregnancy test is negative and is willing to use&#xD;
             effective contraception while on treatment and for at least 3 months after the last&#xD;
             dose of study therapy.&#xD;
&#xD;
          -  patient is accessible and willing to comply with treatment, tissue acquisition and&#xD;
             follow up.&#xD;
&#xD;
          -  patient is willing to provide written informed consent prior to performance of any&#xD;
             study-related procedure.&#xD;
&#xD;
          -  Adequate organ function as defined by the following laboratory values&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Total bilirubin ≤ 1.0 times upper limit of normal (ULN) (&lt; 3 times ULN in patients&#xD;
             with Gilbert's syndrome confirmed by genotyping or Invader UGTIA1 molecular assay)&#xD;
&#xD;
          -  Alkaline phosphatase (AP), ALT, and AST must meet 1 of the following criteria:&#xD;
&#xD;
          -  AP normal AND AST/ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AP ≤ 2.5 times ULN AND ALT/AST ≤ 1.5 times ULN&#xD;
&#xD;
          -  AP ≤ 5 times ULN AND AST/ALT normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory breast cancer, defined as the presence of erythema or induration&#xD;
             involving &gt; 1/3 of the breast&#xD;
&#xD;
          -  Bilateral invasive breast cancer&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Concurrent therapy with any other non-protocol anti-cancer therapy&#xD;
&#xD;
          -  history of any other malignancy within the past 5 years, with the exception of&#xD;
             nonmelanoma skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  pre-existing motor or sensory neurotoxicity ≥ grade 2 by NCI NTCAE version 3.0&#xD;
&#xD;
          -  cardiac disease including any of the following:&#xD;
&#xD;
          -  Myocardial infarction within the past 6 months&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
          -  inflammatory bowel disease or other bowel condition causing chronic diarrhea and&#xD;
             requiring active therapy&#xD;
&#xD;
          -  active, uncontrolled infection requiring parenteral antimicrobials&#xD;
&#xD;
          -  known hypersensitivity to Chinese hamster ovary products or other recombinant human or&#xD;
             humanized antibodies and/or known hypersensitivity to any of the study drugs or their&#xD;
             ingredients (e.g., polysorbate 80 in docetaxel)&#xD;
&#xD;
          -  other medical or psychiatric disorder that, in the opinion of the treating physician,&#xD;
             would contraindicate the use of study drugs or place the subject at undue risk for&#xD;
             treatment complications&#xD;
&#xD;
          -  hormonal agent (e.g., raloxifene, tamoxifen citrate, or other selective estrogen&#xD;
             receptor modulators) for osteoporosis or prevention of breast cancer. subjects must&#xD;
             have discontinued these agents 14 days prior to first baseline biopsy.&#xD;
&#xD;
          -  prior ipsilateral radiotherapy for invasive or noninvasive breast cancer or to the&#xD;
             ipsilateral chest wall for any malignancy&#xD;
&#xD;
          -  prior chemotherapy, radiotherapy, or endocrine therapy for currently diagnosed&#xD;
             invasive or noninvasive breast cancer&#xD;
&#xD;
          -  concurrent ovarian hormonal replacement therapy. Prior treatment must be stopped prior&#xD;
             to first baseline biopsy.&#xD;
&#xD;
          -  male subjects&#xD;
&#xD;
          -  pregnant or lactating subjects&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Hurvitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Hematology Oncology Medical Group, Incorporated - Alhambra</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309-0633</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Heritage Medical Group at Virginia K. Crosson Cancer Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Valley Hematology-Oncology Medical Group</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilshire Oncology Medical Group, Incorporated - Pomona</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767-3021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sansum Medical Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Coast Medical Oncology Corporation</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Hematology Oncology - Solvang</name>
      <address>
        <city>Solvang</city>
        <state>California</state>
        <zip>93463</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Associates Medical Group, Incorporated - Redondo Beach</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of Florida, PA - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Consultants, PA - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Medical Group</name>
      <address>
        <city>Haute Terre</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada - Henderson</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>October 8, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>HER2-positive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

